Jump to content
  • The RRDi is looking for volunteer professional or amateur grant writers who would be willing to apply for corporate grants in behalf of the institute. Our volunteers have received three educational grants from Galderma, and if you are willing to learn how to become a grant writer, jump through all the hoops Galderma requires you to jump through, you could receive a portion of the grant money as a service to the RRDi since this is allowed in our charter. If you are a professional grant writer who has rosacea please consider spending some volunteer time organizing the RRDi's amateur grant writers committee. We prefer grant writers who have rosacea but if you don't have rosacea we still warmly invite you to write grants for our non profit organization. Anyone who wants to join the RRDi as a corporate member may volunteer to learn how to write grants as a volunteer amateur for the RRDi and become in time a professional grant writer. Please join. After logging into your account, contact us that you want to write grants for the RRDi. We will steer you into the correct direction, but basically you will be a volunteer writing grants for the RRDi and if you receive a grant you will be compensated. You may also receive a letter of recommendation if you volunteer for our non profit writing grants, get compensated, and help our non profit receive grants for rosacea research. 

    calligraphy.jpg

    Grant Writers Needed

    The RRDi will pay compensation to the grant writer upon successful allocation of money donated to the RRDi. Applying for Education Grants to Galderma has been our focus. You can also apply for grants to other sources.

    Grant writers are enouraged to join the RRDi and use the private members forum in the GRANT WRITERS forum to discuss a team approach and discuss their concerns in the ASK THE MAC forum with our volunteer Medical Advisory Committee members.

    If you are interested please join the RRDi and enter the members forum and look for the public and private grant writers sections. When you join online, please mention in the volunteer skills box that you are a grant writer or would like to write grants for the RRDi.

    If you have any further questions please use our contact form.

    Steps to Begin the Process to Be a Grant Writer for the RRDi

    (1) Join the RRDi as a member

    Be sure to fill in your contact details in your member profile including your mobile number, mailing address and at least two email addresses. You will be REQUIRED to confirm your primary email address to complete your registration, so please look for the confirmation email and follow the directions. 

    (2)  Be sure to login AFTER you have done step 1 above and be sure that your profile shows all your contact information. 

    (3) Contact us using our contact form indicating you have joined the RRDi as a grant writer volunteer.

    (4) Read ALL the posts in the Grant Writer Public Forum

    Some Helpful Links If You Are Considering Volunteering as a Grant Writer

    How Much Are Grant Writers Paid Per Grant?

    How to Break into the Lucrative World of Grant Writing

    Grants/Proposal Writer Salary in the United States

    How many total hours does it take to write a scientific grant proposal?

    10 Things You Wish You Knew About Grant Writing

    Volunteer Grant Writers

    The RRDi relies on volunteer grant writers. However, if you are successful, we do reward your efforts. If you suffer from rosacea, that is definitely a plus for our organization that you understand what rosacea sufferers are going through and are actually doing something, writing rosacea grants, totally involved in trying to find the cure for rosacea, educating newbie rosaceans, or investigating the cause of rosacea through scientific study. 



  • Posts

    • Antibiotics (Basel). 2024 Mar 17;13(3):270. doi: 10.3390/antibiotics13030270. ABSTRACT Clindamycin is a highly effective antibiotic of the lincosamide class. It has been widely used for decades to treat a range of skin and soft tissue infections in dermatology and medicine. Clindamycin is commonly prescribed for acne vulgaris, with current practice standards utilizing fixed-combination topicals containing clindamycin that prevent Cutibacterium acnes growth and reduce inflammation associated with acne lesion formation. Certain clinical presentations of folliculitis, rosacea, staphylococcal infections, and hidradenitis suppurativa are also responsive to clindamycin, demonstrating its suitability and versatility as a treatment option. This review describes the use of clindamycin in dermatological practice, the mechanism of protein synthesis inhibition by clindamycin at the level of the bacterial ribosome, and clindamycin's anti-inflammatory properties with a focus on its ability to ameliorate inflammation in acne. A comparison of the dermatologic indications for similarly utilized antibiotics, like the tetracycline class antibiotics, is also presented. Finally, this review addresses both the trends and mechanisms for clindamycin and antibiotic resistance, as well as the current clinical evidence in support of the continued, targeted use of clindamycin in dermatology. PMID:38534705 | DOI:10.3390/antibiotics13030270 {url} = URL to article
    • Rev Soc Bras Med Trop. 2024 Mar 25;57:e008042024. doi: 10.1590/0037-8682-0605-2023. eCollection 2024. ABSTRACT Cutaneous involvement in paracoccidioidomycosis (PCM) can exhibit a highly polymorphic spectrum. The infiltrative pattern corresponds to up to 26.6% of observed skin lesions, including sarcoid-like plaques, a rare presentation of cutaneous lesions in PCM. This clinical expression is almost exclusively cutaneous, and its histology reveals a tuberculoid granuloma with a scarcity of fungi, leading to misdiagnosis as other granulomatous diseases. Here, we report a rare form of chronic multifocal paracoccidioidomycosis manifesting as sarcoid-like skin lesions misdiagnosed as granulomatous rosacea in a patient with severe systemic disease. PMID:38537002 | DOI:10.1590/0037-8682-0605-2023 {url} = URL to article
    • Get free samples of Roversol for rosacea while supplies last. 
    • Otol Neurotol Open. 2023 Nov 22;3(4):e043. doi: 10.1097/ONO.0000000000000043. eCollection 2023 Dec. ABSTRACT BACKGROUND: Pulsatile tinnitus (PT) is increasingly recognized as a cardinal symptom of idiopathic intracranial hypertension (IIH). However, clinicians should remain aware of other causes of nonidiopathic or secondary intracranial hypertension manifesting as PT. We present 2 patients with isolated PT (without accompanying headache, blurred vision, and papilledema) thought to be secondary to tetracycline-induced intracranial hypertension. To our knowledge, these are the first cases of PT as the presenting symptom of this condition. CASES: A 41-year-old female (body mass index [BMI] 29 kg/m2) with ocular rosacea was initially treated with minocycline. Shortly after transitioning to oral doxycycline and erythromycin eye ointment, she noted left-sided PT. Her PT resolved after discontinuing doxycycline. In a second case, a 39-year-old female (BMI 19 kg/m2) with acne presented with a three-year history of left-sided PT while on long-term oral doxycycline for many years. She denied visual or auditory changes and atypical headaches. MRI findings were concerning for intracranial hypertension. Three months later, the patient was seen by neuro-ophthalmology, with findings suggesting prior papilledema. The patient reported PT improvement after discontinuing doxycycline. CONCLUSIONS: This case series highlights 2 cases of isolated PT as the sole symptom of intracranial hypertension that resolved with tetracycline cessation. The presentation and unexpected improvement following tetracycline discontinuation are atypical compared with previous reports of tetracycline-induced intracranial hypertension. Clinicians should maintain a high index of suspicion for all types of intracranial hypertension (idiopathic and secondary), even in patients with a lower BMI. Current and prior medications should be reviewed when considering the etiology of intracranial hypertension. PMID:38516546 | PMC:PMC10950181 | DOI:10.1097/ONO.0000000000000043 {url} = URL to article
    • Ocul Immunol Inflamm. 2024 Mar 21:1-8. doi: 10.1080/09273948.2024.2328791. Online ahead of print. ABSTRACT PURPOSE: The objective of this study was to illustrate the changes in ocular findings, meibography, and tear break-up time (TBUT) values in pediatric patients with ocular rosacea following a standardized treatment. METHODS: The study included consecutive patients diagnosed with ocular rosacea, referred to a tertiary hospital between 2021 and 2023. Each patient underwent biomicroscopic examinations, non-invasive TBUT assessments, corneal fluorescein staining (evaluated using the Oxford scoring system), and meibography. The standard treatment protocol involved warm compresses, eyelid hygiene, preservative-free sodium hyaluronate eye drops (administered four times daily), topical azithromycin 1.5% (twice daily for 3 days), topical steroids (loteprednol 0.5%, four times daily for 2 weeks), and either doxycycline 100 mg/day for 14 days or oral suspension of azithromycin 10 mg/kg for 3 days followed by an additional three-day course of treatment administered 10 days later (for patients above and below 14 years of age, respectively). RESULTS: The study included 18 patients, with 10 (55.5%) being female and 8 (44.4%) being male, with a mean age of 9.7 ± 4.5 years (range: 3-18). Four patients displayed cutaneous involvement. The treatments resulted in significant improvements in the Oxford scores, reduction in corneal neovascularization, and increased TBUT (p < 0.001, p = 0.016, p < 0.001, respectively). Meibomian gland loss area also significantly improved post-treatment (27.4 ± 6.7% vs 39.2 ± 13.4%, p = 0.001). CONCLUSION: This study demonstrated that pediatric ocular rosacea patients may exhibit improved meibomian gland function, regression of corneal neovascularization, and enhanced tear film parameters following a standardized treatment protocol that includes both topical and systemic approaches. PMID:38512290 | DOI:10.1080/09273948.2024.2328791 {url} = URL to article
    • JAAD Case Rep. 2024 Feb 19;46:18-22. doi: 10.1016/j.jdcr.2024.02.005. eCollection 2024 Apr. NO ABSTRACT PMID:38496728 | PMC:PMC10943928 | DOI:10.1016/j.jdcr.2024.02.005 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use